Physician profile
Michael C Sims
NPI 1639170350
$4,967.86
in general payments reported to CMS, 2019-2025
37 companies · $19.90 in 2025
The $19.90 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $1,371 · 2021: $1,980 · 2022: $76.04 · 2023: $28.62 · 2024: $51.78 · 2025: $19.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.03 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $495.13 | 2019-2024 | Breztri, Airsupra |
| Astellas Pharma US INC | $479.82 | 2019-2024 | Veozah |
| Abbvie INC. | $406.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $327.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $240.10 | 2019-2021 | |
| Amarin Pharma, INC. | $238.84 | 2019-2021 | |
| Eisai INC. | $210.33 | 2020-2021 | |
| Amgen INC. | $207.84 | 2019-2021 | |
| Lilly USA, LLC | $202.00 | 2019-2021 | |
| Pfizer INC. | $193.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $126.18 | 2019-2021 | |
| Esperion Therapeutics, INC. | $121.65 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $120.00 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $110.84 | 2019-2021 | |
| Allergan, INC. | $94.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.37 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $46.65 | 2021 | |
| Glaxosmithkline, LLC. | $40.74 | 2019-2021 | |
| Adlon Therapeutics L.P. | $33.10 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $28.90 | 2019 | |
| Aytu Biopharma, INC. | $26.85 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.10 | 2021 | |
| Vivus LLC | $21.07 | 2019 | |
| Therapeuticsmd, INC. | $20.42 | 2019 | |
| Mylan Specialty L.P. | $19.75 | 2020 | |
| Daiichi Sankyo INC. | $17.53 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.29 | 2021 | |
| Abbott Laboratories | $14.68 | 2021 | |
| Horizon Therapeutics Plc | $14.56 | 2021 | |
| Radius Health, INC. | $14.39 | 2021 | |
| Genentech USA, INC. | $14.07 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $13.86 | 2019 | |
| Dexcom, INC. | $12.38 | 2021 | |
| Medtronic USA, INC. | $11.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.